This contribution describes process development leading to the production of 1-(1-pyridin-2-yl methyl-piperidin-4-yl)-1H-indole (11). The title compound 11 was produced via a Leimgruber−Batcho indole synthesis using key intermediates 2-(2,2-dimethoxyethyl)benzenamine (6) and, 1-(2-pyridinylmethyl)-4-piperidinone camphor sulfonate (9). Direct crystallization of 11 from IPA or ethanol−water was developed to provide (11) with <1% impurities and high yield (78%). The combined process leads to a five-step synthesis of 11 that was efficient and reflected Eli Lilly and Company's commitment to implementation of environmental friendly processes whenever feasible.

中文翻译：

---

1-（1-吡啶-2-基甲基-哌啶-4-基）-1 H-吲哚的制造工艺的发展：蛋白激酶C抑制剂LY317615的关键中间体

该贡献描述了导致产生1-（1-吡啶-2--2-基甲基-哌啶-4-基）-1H-吲哚的方法开发（11）。通过Leimgruber-Batcho吲哚合成，使用关键中间体2-（2,2-二甲氧基乙基）苯胺（6）和1-（2-吡啶基甲基）-4-哌啶酮樟脑磺酸盐（9），生产标题化合物11。从IPA或乙醇水中直接结晶11已开发出可提供（11）杂质<1％和高产率（78％）。合并的过程导致11的五步综合 这是有效的，反映了礼来公司（Eli Lilly）和公司对在可行的情况下实施环保流程的承诺。